Victoria, British Columbia - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company) has announced significant developments in both its financial reporting schedule and product offerings. Below, we outline the key updates pertaining to these latest announcements.’
Financial Results Rescheduled
ImmunoPrecise Antibodies Ltd. has rescheduled the release of its financial results for the full fiscal year 2024. Initially slated for July 25, 2024, the release has been moved to Monday, July 29, 2024. An earnings call will be held the same day at 10:30 AM Eastern Time to discuss these results and recent business highlights.
The rescheduling was deemed necessary to provide the Company’s auditors with additional time to complete the valuation calculations on goodwill. Comprehensive financial results and an overview of business performance are expected to be covered during the upcoming call.
Launch of LENSai API by BioStrand
In other significant news, IPA announced the immediate commercial offering of a groundbreaking software named LENSai API through its subsidiary, BioStrand. This advanced AI-driven platform, designed for drug discovery, is expected to revolutionize the biotherapeutics sector.
The customizable interface of LENSai API is tailored for AI-driven drug discovery applications, providing unprecedented capabilities in identifying potential drug candidates. Detailed information about the software solution is to be disclosed today at 2:00 PM ET, with a live presentation to follow.
Summary
These developments underscore ImmunoPrecise Antibodies Ltd.’s commitment to leveraging advanced technologies like artificial intelligence to drive progress in biotherapeutics. The rescheduled financial results announcement ensures thorough and accurate reporting, while the launch of LENSai API by BioStrand marks a significant milestone in AI-driven drug discovery.
Stay tuned for further updates and an in-depth look into the LENSai API during today’s detailed presentation.’
Comments